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Quantification and localization of 
oncogenic receptor tyrosine kinase 
variant transcripts using molecular 
inversion probes
Corina N. A. M. van den Heuvel1, Arvid I. Das2, Tessa de Bitter2, Femke Simmer2,  
Thomas Wurdinger3, Miguel Angel Molina-Vila4 & William P. J. Leenders1
Oncogenic membrane receptor tyrosine kinases such as MET and EGFR, or auto-active variants thereof, 
are important targets for cancer precision therapy. Targeted inhibition of these oncogenic receptors 
however invariably leads to resistance, resulting from acquisition of resistance-inducing mutations or 
from selective outgrowth of a priori resistant tumour cells. Most applied molecular protocols cannot 
distinguish between intracellular and intercellular heterogeneity of oncogene (variant) expression, 
which may lead to misinterpretation of the molecular make-up of a cancer and suboptimal application 
of targeted therapies. We here combined two related techniques to allow semiquantitative and 
localized in situ detection of specific transcript splice variants using single molecule molecular inversion 
probe (smMIP)-based next generation sequencing and padlock probe-based rolling circle amplification, 
respectively. We show highly specific padlock probe-based multiplex detection of MET, METΔ7-8 and 
METΔ14 transcripts, lacking exons 7–8 and exon 14 respectively, and of EGFR and the auto-active 
EGFRvIII, lacking exons 2–7. The combination of quantitative transcript variant detection with smMIPs 
and transcript localization using padlock probes can be used for detection of oncogenic transcripts on 
the single-cell level, allowing study of tumour heterogeneity. Visualization of tumour heterogeneity can 
shed light on the biology underlying drug resistance and potentially improve targeted therapeutics.
Membrane receptor tyrosine kinases, e.g. EGFR, FGFR, IGF1-R, MET, AXL, KIT, RON, VEGFRs and PDGFRs1, 
have become important targets for cancer precision therapy. Although inhibition of the oncogenic products 
of these genes frequently leads to initial responses, experience is that eventually treatment-resistant tumours 
develop. Treatment failure may result from intrinsic intratumoural heterogeneity or from acquisition of 
resistance-inducing mutations2–4. An example of the latter is acquisition of EGFRT790M or EGFRC797S mutations 
in non small cell lung cancers upon treatment with the EGFR tyrosine kinase inhibitor erlotinib5,6. Novel pre-
cision medicines have been developed that specifically inhibit these mutant EGFR variants7. Formally however, 
it is unclear whether such aberrations are acquired de novo or whether a priori resistant cells pre-existed in the 
primary tumour, experiencing a growth advantage and eventually replacing the treatment-sensitive tumour bulk. 
This is a highly important question, since in the latter case patients should be treated with combination therapy 
comprising relevant tyrosine kinase inhibitors at start. Therefore it is important to investigate heterogeneity of 
expression of tyrosine kinases, but also other oncogenes, in tumours in more detail.
Molecular research as well as diagnostics of cancer currently consists of analysis of genomic DNA which is 
extracted from cancer tissues that also contain non-tumour cells. In these situations it is impossible to assign 
wild-type alleles to cancer- or stromal cells, or to detect tumour heterogeneity. Examples of oncogenic receptors 
are the MET and EGFR oncogenes, of which different auto-active variants exist. The METΔ7-8 variant results 
from a ~2 Kb intragenic deletion which results in spliced mRNA lacking exons 7 and 8. This variant, that misses 
only 80 amino acids in the ectodomain, is expressed in 6% of high-grade gliomas, remains intracellularly and 
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its activation is ligand independent8. METΔ14 is a splice variant lacking exon 14, a result of exon-skipping point 
mutations in splice sites9,10, and is hyperactive due to increased protein stability. METΔ14 is detected in 0.4% of 
glioma and 3–4% of non-small cell lung carcinoma (NSCLC) cases9–12. Increased MET (variant) expression has 
been described for NSCLC under gefitinib treatment and may represent a rescue kinase for EGFR inhibition13–16.
A second example of oncogene aberration is EGFRvIII. Whereas EGFR is amplified in 50% of glioblastomas, 
half of these events is accompanied by an intragenic deletion, resulting in EGFR transcripts lacking exons 2–79,17. 
Protein products of this transcript lack a large part of the extracellular domain and are auto-active. Because the 
EGFRvIII protein contains a neo-epitope at the exon 1–8 junction, it is tumour specific and therefore of consid-
erable interest for targeted therapies18,19. In glioblastoma, expression of this variant emerges after initial EGFR 
amplification and is heterogeneous, being more prominent in diffuse infiltrating areas of the brain17. Importantly, 
this spatial heterogeneity cannot be inferred from genetic analysis. This highlights the need for expression anal-
ysis on the single-cell level.
In this study, we combine single molecule molecular inversion probe (smMIP) targeted transcriptome 
sequencing20,21 (Fig. 1) with in situ detection of transcript splice variants using padlock probe-based rolling circle 
amplification22–26 (Fig. 2). We show that we are able to specifically and semiquantitatively detect transcript vari-
ants in RNA samples from both cell lines and xenografts using smMIPs, and we demonstrate how in situ padlock 
probe rolling circle amplification adds essential information on transcript localization and tumour heterogeneity.
Results
To investigate whether padlock assays can be used for specific in situ detection of oncogene transcripts, we here 
examined expression of MET and EGFR and auto-active splice variants of these tyrosine kinases, in a cohort of 
cell lines and xenografts with defined EGFR and MET expression. To set up the technique we used cell lines E98 
and its corresponding xenograft (E98-FM, METΔ7-8 amplification)8, cell lines Hs746T (METΔ14, high expression), 
Figure 1. Quantitative detection of transcript splice variants using smMIPs. (a) Schematic overview of the 
method. mRNA is reverse transcribed into cDNA using random primers. SmMIP probes hybridize to the 
target region of interest, leaving a gap of ~112 nucleotides. The gap is filled by primer extension and ligation, 
whereafter all remaining linear smMIPs, RNA and cDNA are removed by exonuclease treatment. All circular 
smMIPs are PCR amplified using a unique barcoded reverse primer for each sample. Resulting reads are 
mapped against reference transcriptomes, normalized to the total read count within a sample (FPM), and 
averaged per transcript variant. (b) Design of smMIP probes. To determine the total expression of a gene, 
smMIPs were designed against shared parts of the transcript of interest (upper panel). For specific detection of 
splice variants smMIPs were designed to target variant-specific exon-exon junctions (for example the exon6–9 
junction for METΔ7-8), either covering the junction with the gap or the ligation/extension probe (lower panel 
left and right, respectively). Note that for graphical representation, the figure is not to scale.
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H596 (METΔ14, low expression), U87-EV (EGFRwt, low expression), U87-EGFRvIII (over-expression)27, and xen-
ograft E468 (EGFR amplification)28. Relative protein expression levels of MET and EGFR in the different cell lines 
and xenografts are shown in Fig. 3a. By PCR analysis we confirmed the MET transcript status of E98, Hs746T and 
H596, and EGFR transcript mutation status of E468, U87-EV and U87-EGFRvIII (Fig. 3b). We semiquantitatively 
determined transcript variant-specific expression levels of MET and EGFR in all cell lines and xenografts using 
smMIPs (Fig. 3c).
We first tested the specificity of the MET-targeting padlock probes on cell lines with known MET status. 
Single-probe assays with padlock probe MET7,8 resulted in fluorescent signal in Hs746T, but not in E98 cells. 
Conversely, single-probe assays with padlock probe MET6–9 resulted in fluorescent signal in E98, but not in 
Hs746T cells (Fig. 4a). These results are in line with the fact that E98 cells exclusively express METΔ7-8, while 
Hs746T cells only express METexon7–8wt transcripts, confirming the specificity of MET7,8 and MET6–9 probes. 
Similarly, we performed single-probe padlock assays with the MET14 and MET13–15 probes on E98 cells in 
which no METΔ14 is expressed, and Hs746T and H596 cell lines, expressing METΔ14. As expected, in E98 cells 
METexon14wt transcripts were readily detected with probe MET14, while the assay was negative when performed 
with the MET13–15 probe (Fig. 4b upper panel). Conversely, Hs746T and H596 cells were positive when assayed 
with the padlock MET13–15 probe, and negative with the MET14 probe (Fig. 4b middle and lower panels). Numbers 
of fluorescent spots in H596 cells were lower than in Hs746T cells, in agreement with the lower levels of MET 
protein that we detected by western blot in these cell lines (Fig. 3a) and lower levels of MET transcript as detected 
by smMIP-sequencing (Fig. 3c).
Having confirmed the specificity of these probes, we subjected E98 and Hs746T cells to a combination of 
MET7,8 and MET6–9 probes, and MET14 and MET13–15 probes, respectively. This duo-probe padlock assay allows 
Figure 2. In situ detection of whole-exon deletion splice variants using padlock probes. (a) Schematic overview 
of the method. mRNA is converted into localized cDNA molecules, which can be targeted through padlock 
probe hybridization and rolling circle amplification. Rolling circle products (RCPs) can then be detected with 
fluorescently labeled probes. Nucleic acid bridges in the BNA primer are depicted in green, padlock probe target 
sites are depicted in blue and padlock probe detection sites are depicted in red. (b) Design of padlock probes 
targeting METexon7–8wt, METΔ7-8, METexon14wt, METΔ14, EGFRwt and EGFRvIII. For specific detection of 
transcript splice variants, padlock probes were designed to target the mutation-specific exon-exon junction 
(detected with magenta fluorescence). For distinctive detection of their associated wild-type variants, padlock 
probes were targeted at the exon(s) missing in the exon deletion transcripts (detected with green fluorescence). 
Note that for graphical representation, the figure is not to scale.
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duplex detection of wild-type (detected in green) and mutant variants (detected in magenta) of the same RNA 
transcript simultaneously. The selectivity of the padlock probes was preserved when mutant-specific probes were 
applied together with their corresponding wild-type probe, and also the efficiency was not notably affected (Fig. 5).
After successful and specific detection of MET splice variants in cell lines, we tested our duo-probe padlock 
assay on FFPE xenograft material. We subjected serial E98-FM FFPE tissue slides, carrying the METΔ7-8 muta-
tion but with a wild type exon 14 allele, to duo-probe padlock assays using a combination of probes MET6–9 and 
MET7,8 (Fig. 6b), MET13–15 and MET14 (Fig. 6c), or MET14 and MET6–9 (Fig. 6d). H&E sections serial to the pad-
lock assay tissues are depicted in Fig. 6a. Both METΔ7-8 and METexon14wt transcripts were specifically detected in 
E98 xenograft tissue, without detection spots for METexon7–8wt or METΔ14 transcripts, respectively (Fig. 6b,c). 
We could visualize different tumour areas with high and low expression of the targeted MET transcripts (Fig. 6b,c, 
left and middle panels, respectively). Note that normal tissue (right part of right panels) was completely negative. 
A double-positive padlock assay targeting METexon14wt and METΔ7-8 on E98 xenograft tissue showed specific 
detection of both transcripts simultaneously (Fig. 6d). Probe specificity is again highlighted at the tumour border 
(Fig. 6d, right panel). Although both padlock probes were readily identified in these sections, co-localization 
Figure 3. Expression levels and mutation status of MET and EGFR in relevant cell lines and xenografts. (a) 
western blot of cell lines E98, Hs746T and H596, U87-EV, U87-EGFRvIII, and xenografts E98-FM and E468, 
showing relative (total) MET and EGFR expression. Note that MET shows two proteins of different sizes, 
corresponding to the preform and the processed form of the protein8. (b) Left: MET PCR on cell lines E98, 
Hs746T and H596 to confirm METΔ7-8 and METΔ14 mutation status. Right: EGFR PCR on cell lines U87-EV 
and U87-EGFRvIII, and xenograft E468, to confirm EGFRwt and EGFRvIII status. (c) SmMIP targeted 
transcriptome profiling of MET (left) and EGFR (right) quantifies variant-specific expression levels in cell lines 
and xenografts. While E98 cells and xenografts express the METΔ7-8 variant, Hs746T and H596 predominantly 
express the METΔ14 variant. U87 cells express METwt transcripts. EGFRwt transcript expression is present in 
Hs746T, H596, U87 and E468 cells and xenografts, while the EGFRvIII variant is only present in the U87-
EGFRvIII cell line.
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was only occasionally observed (see Supplementary Fig. 2, arrows). This is possibly due to the low sensitivity of 
the padlock probe assay. Of note, signals were slightly decreased in the double-positive assay as compared to the 
single-positive padlock assays. Although we could not quantify this, we attribute this to competition of padlock 
probes on the same transcript.
Figure 4. Single-probe in situ mutation detection of MET using padlock probe rolling circle amplification on 
cell lines. (a) In situ detection of METexon7–8wt and METΔ7-8 transcripts in E98 and Hs746T cells using padlock 
probes MET7,8 and MET6–9, respectively. METexon7–8wt transcripts are displayed as green RCPs, METΔ7-8 
transcripts are displayed as magenta RCPs. Cell nuclei are shown in grey. Original magnification 40x. (b) In situ 
detection of METexon14wt and METΔ14 transcripts in E98, Hs746T and H596 cell lines using padlock probes 
MET14 and MET13–15, respectively. METexon14wt transcripts are displayed as green RCPs, METΔ14 transcripts 
are displayed as magenta RCPs. Cell nuclei are shown in grey. Original magnification 40x.
www.nature.com/scientificreports/
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Similar to the padlock assays targeting MET, we performed padlock assays targeting EGFRwt and EGFRvIII 
transcripts. We subjected U87-EV (EGFRwt) and U87-EGFRvIII overexpressing cell lines to a duplex assay to 
detect EGFRwt and EGFRvIII transcripts, using padlock probes EGFR2,3 (green) and EGFR1–8 (magenta), respec-
tively. In U87-EV cells this assay resulted in fluorescent signal for EGFRwt, while EGFRvIII specific transcripts 
were abundantly detected in U87-EGFRvIII overexpressing cells (Fig. 7a). In U87-EGFRvIII cells no EGFRwt 
signals were detected in the duplex assay, probably because of the low abundance of EGFRwt transcripts in these 
cells, compared to high overexpression of EGFRvIII transcripts. Note that the number of EGFRwt fluorescent spots 
in U87-EV cells is much lower than the number of EGFRvIII spots in U87-EGFRvIII cells, which corresponds 
to the difference in EGFR expression (Fig. 3a,c). We also subjected EGFRwt expressing E468 xenograft tissue to a 
duplex EGFR padlock assay. Figure 7b shows specific detection of EGFRwt transcripts.
Discussion
To be able to investigate tumour heterogeneity with respect to oncogene expression, we applied padlock probe 
rolling circle amplification to indentify EGFR, MET and the whole-exon deletion splice variants of these onco-
genes that play a role in, among others, glioma and NSCLC1,5,16,29–31. Simultaneous in situ detection of tyrosine 
kinase splice variants with their associated wild-type variants enables visualization of tumour heterogeneity in 
FFPE tissue sections, material which is routinely used in diagnostics and can be preserved for years.
In recent years, articles have reported on the use of padlock probes for in situ analysis of single-nucleotide 
transcript variants22,24 and fusion transcripts23. Here, we adapted these protocols to allow in situ identification 
of whole-exon deletion splice variants. Probe specificity was validated in single-probe assays on cell lines with 
known MET or EGFR status, and was preserved in duplex padlock assays. As for now, a drawback is low sensitiv-
ity of padlock probe assays, possibly explaining the lack of co-localization of MET14 and MET6–9 probes in Fig. 6d. 
The distinction between intercellular and intracellular tumoural heterogeneity, with different oncogene variants 
being present within the same cell or with subclones of cells carrying different oncogene variants, respectively2,3,32, 
can therefore not be made. This distinction is important since cells co-expressing different tyrosine kinases that 
initiate similar signalling pathways, will respond differently to drugs than cells expressing only the targeted 
kinase. Low sensitivity of padlock probe assays has been described before22,24,25. However, the reason is not clear 
and may be related to any of the complex steps in the procedure, including fixation method/RNA quality, RNA 
secondary structures that hamper effective in situ reverse transcription, and the presence of single nucleotide 
polymorphisms (SNPs) impeding hybridisation of the BNA probe and the padlock probe. Improvement of sen-
sitivity of the method is necessary to detect co-expression of different transcripts in one cancer cell. However, the 
high specificity of the padlock assay will allow the investigation of intratumoural, intercellular heterogeneity of 
splice variant transcript expression. To allow successful padlock assays on clinical tissue, the essentiality of RNA 
integrity probably requires that tumour tissue is fixated shortly after surgery or biopsy in proper preservatives.
For smMIP-based targeted RNA sequencing we have observed a variance in efficacy between different 
smMIPs targeting the same transcript. We have reported that the average of five smMIPs targeting one transcript 
gives a reliable estimate of the expression level of a transcript21. Because padlock assays rely on the hybridisation 
of one individual probe for each transcript variant, these are not suitable for quantification of transcript (variant) 
expression levels. In situ rolling circle amplification using padlock probes does allow visualization of intercellular 
heterogeneity within tumour tissues. In contrast, smMIP-based targeted RNA sequencing allows quantitative and 
specific detection of splice variants, but does not enable visualization of tumour heterogeneity and localization 
of specific transcripts. The combination of both techniques possibly allows differentiation between intrinsic and 
acquired transcript expression (induced tumour heterogeneity), and between intrinsic and acquired treatment 
resistance development. This is an interesting aspect for future studies and may give more insight into tumour 
Figure 5. Multi-plex in situ mutation detection of MET using padlock probe rolling circle amplification 
on cell lines. In situ duo-probe detection of METexon7–8wt and METΔ7-8 transcripts in E98 cells (left) and 
METexon14wt and METΔ14 transcripts in Hs746T cells (right) using padlock probes MET7,8 and MET6–9, and 
MET14 and MET13–15, respectively. METexon7–8wt and METexon14wt transcripts are displayed as green RCPs, 
METΔ7-8 and METΔ14 transcripts are displayed as magenta RCPs. Cell nuclei are shown in grey. Original 
magnification 40x.
www.nature.com/scientificreports/
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Figure 6. Multi-plex in situ mutation detection of MET using padlock probe rolling circle amplification on 
E98-FM FFPE xenograft tissue. (a) Serial H&E stainings. (b) In situ duo-probe detection of METexon7–8wt 
and METΔ7-8 transcripts using padlock probes MET7,8 and MET6–9, respectively. (c) In situ duo-probe 
detection of METexon14wt and METΔ14 transcripts using padlock probes MET14 and MET13–15, respectively. 
(d) In situ duo-probe detection of METexon14wt and METΔ7-8 transcripts using padlock probes MET14 and 
MET6–9, respectively. Wild-type transcripts are displayed as green RCPs, mutant transcripts are displayed 
as magenta RCPs. Cell nuclei are shown in grey. Note that in all assays the tumour border emphasizes the 
specificity of the padlock probes, showing no fluorescent detection spots in normal brain tissue (right figures, 
original magnification 20x). Compare the left and middle panels for each assay, visualizing differences in 
transcript expression in different tumour areas. Inserts give a zoomed view of the underlying image. Original 
magnification 40x.
www.nature.com/scientificreports/
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resistance biology. This potentially has implications for targeted therapy, because patients with pre-existent resist-
ant tumour clones may benefit significantly from combination therapies at start.
In conclusion, we here show the high value of combining two molecular inversion probe techniques. Using 
smMIP targeted transcriptomics we can quantitatively measure transcript variant-specific gene expression. 
Additionally, padlock probe rolling circle amplification enables specific and local visualization of transcript var-
iants in situ, however with low efficacy. The technique of smMIP-based RNA splice variant sequencing can be 
easily expanded with smMIP probes to detect other transcript variants, and can serve as an important tool for 
detection of molecular heterogeneity and investigation of the role of splice variants in therapy resistance.
Materials and Methods
Cell lines and xenografts. Cell lines Hs746T and H596 were obtained from ATCC (Manassas, VA). Cell 
lines E9828, Hs746T, H596, U87-EV and U87-EGFRvIII (obtained from dr. Web Cavenee, Ludwig Cancer Inst., 
USA27) were cultured at 37 °C in the presence of 5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM) con-
taining 4.5 g/L glucose and 4 mM L-glutamin (Lonza, Basel, Switserland), 10% fetal calf serum (FCS, Gibco, 
Waltham, MA, USA) and 40 µg/ml gentamycin (Centrafarm, Ettenleur, The Netherlands). The METΔ7-8-
expressing astrocytoma cell line E98 and the EGFR-expressing astrocytoma line E468, as well as the generation of 
orthotopic xenografts thereof, has been described before8,28.
Western blot. Cells were lysed in 1x RIPA buffer (Cell Signaling Technology, CST, Danvers, MA) with 1 mM 
phenylmethylsulfonyl fluoride (PMSF), according to manufacturer’s instructions. Protein lysates were subjected 
to electrophoresis on 10% SDS-PAGE gels and electroblotted onto nitrocellulose membranes (Whatman Optitran 
BA-S85, GE Healthcare, Little Chalfont, UK). After blocking aspecific binding sites in blocking buffer (1:1 PBS/
Odyssey blocking buffer [LI-COR Biosciences, Lincoln, NE, USA]), blots were incubated o/n at 4 °C with pri-
mary antibodies: rabbit-anti-MET (1:2500, CST, #8198), rabbit-anti-EGFR D38B1 (1:2000, CST, #4267) and 
mouse-anti-GAPDH (1:5000, Abcam, ab8245). Primary antibodies were detected with appropriate IRDye680- or 
IRDye800-conjugated secondary antibodies (Invitrogen Molecular Probes, Waltham, MA, USA) incubated 1 hr at 
RT shielded from light. Signals were visualized using the Odyssey imaging system (LI-COR Biosciences, Lincoln, 
NE, USA).
Figure 7. Multi-plex in situ mutation detection of EGFR using padlock probe rolling circle amplification on 
cell lines and E468 xenograft tissue. A) In situ duo-probe detection of EGFRwt and EGFRvIII transcripts using 
padlock probes EGFR2,3 and EGFR1–8, on U87-EV and U87-EGFRvIII cells (original magnification 40x). B) 
In situ duo-probe detection of EGFRwt and EGFRvIII transcripts using padlock probes EGFR2,3 and EGFR1–8, 
on E468 xenograft FFPE tissue (original magnification 20x). EGFRwt transcripts are displayed as green RCPs, 
EGFRvIII transcripts are displayed as magenta RCPs. Cell nuclei are shown in grey.
www.nature.com/scientificreports/
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PCR. RNA was isolated from cell lines and snap-frozen xenograft tissue using TRIzol reagent (Life 
Technologies, ThermoFisher Scientific, Waltham, MA, USA) and reverse transcribed with Superscript II 
(Invitrogen, ThermoFisher Scientific, Waltham, MA, USA) using random hexamer primers, according to the 
manufacturer’s instructions. RT-PCR was performed using Amplitaq Gold 360 mastermix (Applied Biosystems, 
Life Technologies), which for PCR on MET was supplemented with 1 mM MgCl2 and 20 µg/ml BSA (both 
New England Biolabs, Ipswich, MA, USA). To distinguish METΔ7-8 transcripts from their wild-type variant 
(METexon7–8wt), primers MET1997Fw (5′-CTCCTTGGAAATGAGAGCTG-3′, forward, located in exon 6) and 
MET2393Rv (5′-AGATGCTTGTCTCTCGGTTG-3′, reverse, located in exon 9) were used. This PCR results in 
a 397-bp amplicon for METexon7–8wt and a 157-bp product for METΔ7-8. To distinguish METΔ14 transcripts and 
their wild-type variant (METexon14wt) primers MET2982Fw (5′- CAGGATTGATTGCTGGTGTTGTCTC-3′, 
forward, located in exon 13) and MET3252Rv (5′- CGGCATGAACCGTTCTGAGATG-3′, reverse, located in 
exon 15) were used, resulting in a PCR product of 271 bp for METexon14wt and 130 bp for METΔ14. To detect 
EGFRwt transcripts primers EGFR819Fw (5′-GATATCACCATGCGACCCTCCGGG-3′, forward, located in 
exon 5) and EGFR1567Rv (5′-CGACTGCAAGAGAAAACTGA-3′, reverse, located in exon 12) were used, 
resulting in a 749-bp product for EGFRwt. For detection of EGFRvIII transcripts in U87-EGFRvIII cells, prim-
ers EGFR258Fw (5′-GATATCACCATGCGACCCTCCGGG-3′, forward, located in exon 1) and EGFR1567Rv 
(5′-CGACTGCAAGAGAAAACTGA-3′, reverse, located in exon 12) were used, resulting in a 529-bp product 
for EGFRvIII. PCR conditions were: initial denaturation of 3 min at 95 °C, followed by 36 cycles of denaturation at 
95 °C, 30 s; annealing at 60 °C, 30 s; elongation at 72 °C, 30 s, and a final elongation step of 5 min at 72 °C.
smMIP targeted RNA sequencing. RNA from cell lines and snap-frozen xenograft tissue was isolated and 
converted to cDNA as described under ‘PCR’. The smMIP method and its application for targeted transcriptome 
sequencing has been described before20,21 and is depicted in Fig. 1a. SmMIPs were designed against target regions 
of interest (UCSC human genome assembly hg19, and variant-specific FASTA sequences) with ligation and exten-
sion probes localized on different exons, depending on the splice variant to be detected, and leaving a gap of 
maximum 112 nt. SmMIPs were designed based on the MIPgen algorithm as described by Boyle et al.33 and added 
to a large panel of previously designed smMIPs21. The panel of phosphorylated smMIPs was hybridized to cDNA 
after which the gap was filled by primer extension and ligation. Non-reacted smMIPs and remaining RNA and 
cDNA were removed by exonuclease treatment, followed by PCR amplification of the circularized smMIP library 
using a unique barcoded reverse primer for each sample. After library pooling and purification using AMPureXP 
beads (Beckman Coulter Genomics, High Wycombe, UK) smMIP-PCR libraries were sequenced on the Illumina 
Nextseq platform (Illumina, San Diego, CA) at the Radboudumc sequencing facility. Reads were mapped against 
the reference transcripts (UCSC human genome assembly hg19 and variant-specific FASTA sequences) using 
the SeqNext module of JSI SequencePilot version 4.2.2 build 502 (JSI Medical Systems, Ettenheim, Germany). 
The random 8xN nucleotide tag flanking the ligation probe was used to reduce PCR amplicates to one consensus 
read originating from the same smMIP (unique read). Read counts for each smMIP were normalized to the total 
read count within a sample and multiplied by 106 (Fragments per Million, FPM). Individual transcript levels were 
expressed as mean FPM of all smMIPs targeting that transcript.
SmMIPs were designed against transcript variants of MET (total MET, METΔ7-8, METΔ14) and EGFR (total 
EGFR, EGFRvIII). SmMIP sequences are depicted in Table 1. An example of smMIP design for total MET (tran-
script variant 2) and METΔ7-8 is depicted in Fig. 1b. To determine the cumulated expression of all MET tran-
script variants, smMIPs were designed against shared parts of the transcripts (total MET). To enable detection 
of truncated transcripts, smMIPs were designed against splice variant-specific exon-exon junctions, either with 
the maximum 112 nt gap or the ligation/extension probe covering the exon-exon junction (exon 6–9 junction for 
METΔ7-8). SmMIPs were designed in a similar way for METΔ14, total EGFR and EGFRvIII.
Padlock probe design. The protocol for padlock probe rolling circle amplification and the design of pad-
lock probes with associated bridged nucleic acid (BNA) primers was adapted from Weibrecht et al.26 and is sum-
marized in Fig. 2a,b. Wild-type transcripts were distinctively detected with padlock probes targeting ‘normal’ 
exon-exon junctions that are missing in the exon-deletion transcript variants. For specific detection of splice 
variants, padlock probes were designed to target the splice variant-specific MET exon-exon junctions 6–9 (for 
detection of METΔ7-8) and 13–15 (for detection of METΔ14) and EGFR exon-exon junction 1–8 (for detection 
of EGFRvIII, Fig. 2b). To allow dual detection of splice variants together with their associated wild-type tran-
scripts, specific sequences were included in the backbone of the padlock probe allowing detection via hybridi-
zation of complementary fluorescent probes. Bridged Nucleic Acid (BNA) primer, padlock probe and detection 
probe nucleotide sequences, as well as the nomenclature of probes and transcript variants used in this paper, 
are outlined in Table 2. Before use, padlock probes (IDT, Leuven, Belgium) were 5′-phosphorylated using 0.2 
U/µl T4 PNK in 1x PNK buffer A (ThermoFisher Scientific, Waltham, MA, USA) according to manufacturer’s 
instructions.
Padlock probe rolling circle amplification. The protocol for padlock probe rolling circle amplification 
is summarized in Fig. 2a. For padlock assays on cell lines, cells were seeded on 8-well Lab-Tek II chamber slides 
(ThermoFisher Scientific, Waltham, MA, USA) and fixated the following day in 3.7% freshly prepared formalde-
hyde in DEPC-treated PBS (DEPC-PBS) for 30 min at room temperature. Fixated cells were washed twice with 
DEPC-PBS and dehydrated through an ethanol series (70%, 85% and 99.5%). Secure-seals (Grace Bio-Labs inc., 
Bend, Oregon, USA) with a volume of 50 µl (Ø 9 mm, 0.8 mm deep) were mounted on the Lab-Tek slides and 
cells were rehydrated by addition of DEPC-PBS-Tween (DEPC-PBS with 0.05% Tween-20). For tissue analyses, 
formalin-fixed paraffin-embedded (FFPE) sections of E98 xenografts (E98-FM, generated from the E98 cell line) 
and E468 xenografts were deparaffinized and fixated in 3.7% paraformaldehyde (PFA) in diethylpyrocarbonate 
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(DEPC)-treated PBS. Tissue sections were permeabilized with pepsin (2 mg/ml in 0.1 M HCl) and dehydrated 
through an ethanol series (70%, 85% and 99.5%). Secure-seals (Grace Bio-Labs inc., Bend, Oregon, USA) with 
a volume of 250 µl (Ø 20 mm, 0.8 mm deep) were mounted and cells were rehydrated with DEPC-PBS-Tween. 
All following incubation steps were performed within the secure seal chambers, incubated in a hybridizer 
(Dakocytomation, Glostrup, Denmark).
In situ reverse transcription was performed using BNA primers positioned within ≤1 nt from the 5′ end 
of the padlock probe target site (see Table 2 for nucleotide sequences). BNA primer hybridization and mRNA 
reverse transcription were performed o/n at 42 °C using 200 nM of BNA primer (IDT, Leuven Belgium), 20 U/
Transcript
Exon targets
MIP sequence (5′→3′)
Extension Ligation
variant probe probe
Total MET Exon 9 Exon 9–10 GTGGTGGGAGCACAATAACAGGTGTTGNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTCAAACCATTTCAACTGAG
(variant 2) Exon 9 Exon 11 GCATGTCAACATCGCTCTAATTCAGNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTATTCATCCAACCAAATCTTT
METΔ7-8
Exon 6 Exon 6–9 GCACGATGAATACTGTGTCAAACAGNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTTTGAAGGAGGGACAAGGCTG
Exon 6 Exon 9 GCCAACCGAGAGACAAGCATCTTCANNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTAATGAGAGCTGCACCTTGAC
METΔ14
Exon 13 Exon 15 GTTTCCTAATTCATCTCAGAACGGTTCANNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTAATAGTTCAACCAGATC
Exon 13 Exon 15 CAGTCCATTACTGCAAAATACTGTCCACANNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTAAAAAGAGAAAGCAAA
Total EGFR
Exon 1 Exon 2 GGAAATTACCTATGTGCAGAGGAATTATGNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTCTGGAGGAAAAGAAAG
Exon 3 Exon 3 GCAAATAAAACCGGACTGAAGGAGCNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTGTGGCTGGTTATGTCCTCAT
Exon 3 Exon 4 GCCCTGTGCAACGTGGAGAGCATCNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTCTACGAAAATTCCTATGCCTT
Exon 5–6 Exon 6–7 GCCTGGTCTGCCGCAAATTCCGAGACGAANNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTCCAGAAACTGACCAAA
Exon 7 Exon 8 GCCTGTGGGGCCGACAGCTATGAGATGGANNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTTCTACAACCCCACCAC
Exon 9 Exon 10–11 CGTAAAGGAAATCACAGGGTTTTTGCTGANNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTAAACACTTCAAAAACT
Exon 15 Exon 17 GCCCTGGGGATCGGCCTCTTCATNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTACCTGTGCCATCCAAACTGCAC
Exon 
17–18
Exon 
18–19 GCACGGTGTATAAGGGACTCTGGATNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTTGCTGCAGGAGAGGGAGCTT
Exon 18 Exon 19–20 GCCAACAAGGAAATCCTCGATGAAGCNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTAAAAGATCAAAGTGCTGGG
Exon 19 Exon 20 TCTGCCTCACCTCCACCGTGCANNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTAAGTTAAAATTCCCGTCGCTATC
Exon 20 Exon 20 GCTCCCAGTACCTGCTCAACTGGTGTGTNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTTGGACAACCCCCACGT
Exon 21 Exon 21–22 GCAGAAGGAGGCAAAGTGCCTATCAANNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTAGGACCGTCGCTTGGTGCA
Exon 21 Exon 23 GAGTTGATGACCTTTGGATCCAAGCCNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTCGGAAGAGAAAGAATACCA
Exon 
23–24 Exon 25 GCCAAGTCCTACAGACTCCAACNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTCATGGTCAAGTGCTGGATGATAG
Exon 26 Exon 27 GACAGCATAGACGACACCTTCCTCCCAGNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTAGTGCAACCAGCAACAA
Exon 28 Exon 28 GCCACCAAATTAGCCTGGACAACCCTGNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTAGAGACCCACACTACCA
EGFRvIII
Exon 1 Exon 8 GTGGTGACAGATCACGGCTCGTGNNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTGAGAGCCGGAGCGAGCTCTT
Exon 1 Exon 8–9 GCCGCAAAGTGTGTAACGGAATAGGTANNNNNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTCTGGAGGAAAAGAAAG
Table 1. SmMIP nucleotide sequences. Ligation and extension probes are depicted in Italic.
Transcript variant Exon targets (probe)
Nucleotide sequences (5′→3′)
BNA primer Padlock probe Detection probe
METexon7-8wt Exon 7-8 (MET7,8) CAGCCATAGGACCGTATTTCGGCGA
GATCCTGTAATAACAAGTATGTGACATACTGACAAAGTAGCCGTG
ACTATCGACTTGACCAGTTAGCAAAACAGTACATTCTCCTATGTG
Cy5-AGTAGCCGTG 
ACTATCGACT
METΔ7-8 Exon 6-9 fusion(MET6–9)
GGGCTGGGGTATA
ACATTCAAGAAT
TGTGTCAAACAGTATTCTTGGTGACATACTGACACCTCAATGCACA
TGTTTGGCTCCTGACCAGTTAGCAAGTGAGAGCACGATGAATAC
TexRd-XN-CCTCAATGC 
ACATGTTTGGCTCC
METexon14wt Exon 14(MET14)
CACTTCGGGCACTT
ACAAGCCTATC
CACTCCTCATTTGGATAGGCGTGACATACTGACAAAGTAGCCGTG
ACTATCGACTTGACCAGTTAGCAAACGCTACGATGCAAGAGTACA
Cy5-AGTAGCCG 
TGACTATCGACT
METΔ14 Exon 13-15fusion (MET13–15)
TCGGCATGAACCG
TTCTGAGATGAA
ATCAGTTTCCTAATTCATCTGTGACATACTGACACCTCAATGCACAT
GTTTGGCTCCTGACCAGTTAGCAAAAGAGAAAGCAAATTAAAG
TexRd-XN-CCTCAATGCAC 
ATGTTTGGCTCC
EGFRwt Exon 2-3(EGFR2,3)
AGGGCAATGAGGA
CATAACCAGCCA
ACCATCCAGGAGGTGGCTGGGTGACATACTGACAAAGTAGCCGT
GACTATCGACTTGACCAGTTAGCAAAATGATCTTTCCTTCTTAAAG
Cy5-AGTAGCC 
GTGACTATCGACT
EGFRvIII Exon 1-8fusion (EGFR1–8)
CTCGGACGCACGAG
CCGTGATCTGT
GTAATTATGTGGTGACAGATGTGACATATGAAACCTCAATGCTGCTGC
TGTACTAC TGACCAGTTAGCAGGCTCTGGAGGAAAAGAAAG
TexRd-XN-CCTCAATGCT 
GCTGCTGTACTAC
Table 2. BNA primer, padlock probe and detection probe nucleotide sequences. BNA primer Bridged Nucleic 
Acids are depicted in bold. Padlock probe target-specific sequences are depicted in italic. Detection probe 
complementary sequences in the padlock probe are coloured bold italic (wild-type) or italic underline (mutant).
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µl RevertAid H minus M-MuLV reverse transcriptase in 1x M-MuLV reaction buffer (ThermoFisher Scientific, 
Waltham, MA, USA), 1 U/µl RiboLock RNase Inhibitor (ThermoFisher Scientific, Waltham, MA, USA), 500 µM 
dNTP and 0.2 µg/µl BSA (New England Biolabs, Ipswich, MA, USA). Post-fixation was performed with 3.7% 
formaldehyde (5 min) or 3.7% PFA (45 min) for cells or tissues, respectively. FFPE tissues were subsequently 
treated with glycine (2 g/100 ml in DEPC-PBS, 20 min RT) to decrease autofluorescence. Secure seal chambers 
were flushed with DEPC-PBS-Tween. Padlock probes (100 nM) were hybridized to the cDNA and ligated using 
0.5 U/µl Ampligase in 1x Ampligase buffer (Epicentre, Madison, Wisconsin, USA) containing 0.4 U/µl RNase H 
(New England Biolabs, Ipswich, MA, USA), 1 U/µl RiboLock RNase Inhibitor, 0.2 µg/µl BSA, 50 mM KCl and 20% 
formamide (30 min 37 °C, 30 min 45 °C).
Rolling circle amplification of the ligated padlock probe was performed o/n at 37 °C using Phi29 DNA 
polymerase (ThermoFisher Scientific, Waltham, MA, USA). Secure seal chambers were flushed with 
DEPC-PBS-Tween and Phi29 DNA polymerase was added at a concentration of 1 U/µl in 1x Phi29 DNA pol-
ymerase buffer (ThermoFisher Scientific, Waltham, MA, USA) with 1 U/µl RiboLock RNase Inhibitor, 250 µM 
dNTP, 0.2 µg/µl BSA and 5% glycerol. After washing with DEPC-PBS-Tween, rolling circle products (RCPs) 
were visualized by hybridization to 100 nM of corresponding fluorescent detection probe (See Table 2) (IDT, 
Leuven, Belgium) in 1x saline-sodium citrate (SSC) and 20% formamide (37 °C, 30 min). The slides were dehy-
drated through an ethanol series (70%, 85% and 99.5%) and mounted with Vectashield (Vector Laboratories Inc., 
Burlingame, CA, USA) containing 375 ng/ml DAPI for nuclear counterstaining.
Slides were imaged using the Vectra (Caliper Life Sciences, Waltham, MA, USA). Slide analysis was performed 
with the Vectra Automated Quantitative Pathology Imaging System (Version 3.0.3, PerkinElmer Inc., Waltham, 
MA, USA) and inForm Advanced Image Analysis Software (Version 2.2.1, PerkinElmer Inc., Waltham, MA, 
USA). Contrast-enhancement was applied on the resulting images using GIMP version 2.8.20.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request
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